Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-Targeted Prime CAR-T in Relapsed/Refractory Multiple Myeloma
NCT04776330Phase 2Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Mar 2021
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of BCMA targeted prime CAR-T cells in multiple myeloma (MM), sponsored by Chongqing Precision Biotech. Started Mar 2021; status: recruiting.
02
Drugs
BCMA targeted prime CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04776330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776330.